Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis Meeting Abstract
| Authors: | Paz-Ares, L.; Ciuleanu, T. E.; Yu, X.; Salman, P.; Pluzanski, A.; Nagrial, A.; Havel, L.; Kowalyszyn, R.; Audigier-Valette, C.; Wu, Y. L.; Borghaei, H.; Hellmann, M. D.; Brahmer, J.; Reck, M.; Ramalingam, S.; Zhang, L.; Bhagavatheeswaran, P.; Nathan, F. E.; O'Byrne, K. J. |
| Abstract Title: | Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis |
| Meeting Title: | ESMO Immuno-Oncology Congress 2019 |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 11 |
| Meeting Dates: | 2019 Dec 11-14 |
| Meeting Location: | Geneva, Switzerland |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-12-01 |
| Start Page: | mdz453.004 |
| Language: | English |
| ACCESSION: | WOS:000506799900173 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz453.004 |
| Notes: | Meeting Abstract: LBA3 -- Appears on pages xi67-xi68 of the abstract book -- Source: Wos |
